BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 25650440)

  • 1. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma.
    Walker MP; Stopford CM; Cederlund M; Fang F; Jahn C; Rabinowitz AD; Goldfarb D; Graham DM; Yan F; Deal AM; Fedoriw Y; Richards KL; Davis IJ; Weidinger G; Damania B; Major MB
    Sci Signal; 2015 Feb; 8(362):ra12. PubMed ID: 25650440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of FOXP1 in diffuse large B-cell lymphoma.
    Gascoyne DM; Banham AH
    Leuk Lymphoma; 2017 May; 58(5):1037-1051. PubMed ID: 27678023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA PVT1 facilitates DLBCL development via miR-34b-5p/Foxp1 pathway.
    Tao S; Chen Y; Hu M; Xu L; Fu CB; Hao XB
    Mol Cell Biochem; 2022 Mar; 477(3):951-963. PubMed ID: 35098439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
    Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
    Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells.
    van Keimpema M; Grüneberg LJ; Schilder-Tol EJ; Oud ME; Beuling EA; Hensbergen PJ; de Jong J; Pals ST; Spaargaren M
    Haematologica; 2017 Mar; 102(3):573-583. PubMed ID: 27909217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
    Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
    Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.
    Dekker JD; Park D; Shaffer AL; Kohlhammer H; Deng W; Lee BK; Ippolito GC; Georgiou G; Iyer VR; Staudt LM; Tucker HO
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):E577-86. PubMed ID: 26787899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPNMB promotes the progression of diffuse large B cell lymphoma via YAP1-mediated activation of the Wnt/β-catenin signaling pathway.
    Wang Z; Ran X; Qian S; Hou H; Dong M; Wu S; Ding M; Zhang Y; Zhang X; Zhang M; Chen Q
    Arch Biochem Biophys; 2021 Oct; 710():108998. PubMed ID: 34280359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas.
    Bognar MK; Vincendeau M; Erdmann T; Seeholzer T; Grau M; Linnemann JR; Ruland J; Scheel CH; Lenz P; Ott G; Lenz G; Hauck SM; Krappmann D
    Oncogene; 2016 Aug; 35(32):4269-81. PubMed ID: 26776161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both FOXP1 and p65 expression are adverse risk factors in diffuse large B-cell lymphoma: a retrospective study in China.
    Hu CR; Wang JH; Wang R; Sun Q; Chen LB
    Acta Histochem; 2013 Mar; 115(2):137-43. PubMed ID: 22809882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma.
    Sagaert X; de Paepe P; Libbrecht L; Vanhentenrijk V; Verhoef G; Thomas J; Wlodarska I; De Wolf-Peeters C
    J Clin Oncol; 2006 Jun; 24(16):2490-7. PubMed ID: 16636337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription Factor 7-like 2 Mediates Canonical Wnt/β-Catenin Signaling and c-Myc Upregulation in Heart Failure.
    Hou N; Ye B; Li X; Margulies KB; Xu H; Wang X; Li F
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/β-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression.
    Mir R; Pradhan SJ; Patil P; Mulherkar R; Galande S
    Oncogene; 2016 Mar; 35(13):1679-91. PubMed ID: 26165840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/β-catenin signaling pathway.
    Dai R; Wu M; Zhang Y; Zhu Z; Shi J
    Exp Cell Res; 2021 Dec; 409(2):112911. PubMed ID: 34762898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXP1-induced lncRNA CLRN1-AS1 acts as a tumor suppressor in pituitary prolactinoma by repressing the autophagy via inactivating Wnt/β-catenin signaling pathway.
    Wang C; Tan C; Wen Y; Zhang D; Li G; Chang L; Su J; Wang X
    Cell Death Dis; 2019 Jun; 10(7):499. PubMed ID: 31235696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA FIRRE is activated by MYC and promotes the development of diffuse large B-cell lymphoma via Wnt/β-catenin signaling pathway.
    Shi X; Cui Z; Liu X; Wu S; Wu Y; Fang F; Zhao H
    Biochem Biophys Res Commun; 2019 Mar; 510(4):594-600. PubMed ID: 30739786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hematopoietic oncoprotein FOXP1 promotes tumor cell survival in diffuse large B-cell lymphoma by repressing S1PR2 signaling.
    Flori M; Schmid CA; Sumrall ET; Tzankov A; Law CW; Robinson MD; Müller A
    Blood; 2016 Mar; 127(11):1438-48. PubMed ID: 26729899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
    Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
    Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferential expression of truncated isoforms of FOXP1 in primary central nervous system lymphoma.
    Courts C; Brunn A; Montesinos-Rongen M; Siemer D; Hans V; Paulus W; Wiestler OD; Küppers R; Siebert R; Deckert M
    J Neuropathol Exp Neurol; 2009 Sep; 68(9):972-6. PubMed ID: 19680146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.